Medicinal chemistry stands as a dynamic and collaborative discipline, uniting diverse scientific expertise for drug discovery, development, and synthesis. Interdisciplinary teams, comprising synthetic chemists, biologists, pharmacologists, and more, drive the process from molecule inception to clinical trials. Beyond discovery, medicinal chemistry's impact extends throughout clinical development, requiring substantial drug quantities for trials. The field evolved with cutting-edge technologies such as combinatorial chemistry, microwave synthesis, and high-throughput screening. This cohesive approach caters to the demand for innovative pharmaceuticals, propelling the global medicinal chemistry for drug discovery market's growth.
According to Data Bridge Market Research, the Global Medicinal Chemistry for Drug Discovery Market is growing with a CAGR of 13.5% in the forecast period of 2022 to 2029 and is expected to reach USD 12,173.97 million by 2029.
“Increasing need for safe and effective drugs drive the market growth”
The increasing need for safe and effective drugs acts as a significant driver in the global medicinal chemistry for drug discovery market. With growing health concerns and evolving diseases, there's a heightened demand for pharmaceutical interventions that offer improved efficacy and reduced side effects. Medicinal chemistry plays a pivotal role in designing compounds with targeted interactions, enhancing drug development success rates. This driver is further fueled by advancements in molecular understanding, enabling researchers to create innovative molecules tailored for specific therapeutic purposes, meeting the global demand for enhanced healthcare solutions.
What restraints the growth of global medicinal chemistry for drug discovery market?
“Technical risks in drug discovery”
Technical risks in drug discovery pose a notable restraint in the global medicinal chemistry market. Developing new pharmaceutical compounds involves intricate processes with uncertainties related to compound stability, toxicity, and efficacy. These challenges can lead to costly failures at various stages of development, impeding progress and draining resources. The complexity of molecular interactions, unpredictable biological responses, and potential adverse effects contribute to these risks.
Segmentation: Global Medicinal Chemistry for Drug Discovery Market
Medicinal chemistry for drug discovery market is segmented on the based on the basis of process, design, drug type, therapeutic area, and end user.
- On the basis of process, the global medicinal chemistry for drug discovery market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation.
- On the basis of design, the global medicinal chemistry for drug discovery market is segmented into fragment-based variation, structure-based drug deisgn, diversity oriented synthesis, chemogenomics, natural products and others.
- On the basis of drug type, the global medicinal chemistry for drug discovery market is segmented into small molecules and biologics.
- On the basis of therapeutic area, the global medicinal chemistry for drug discovery market is segmented into oncology, infectious and immune system disease, neurology, cardiovascular disease, digestive system disease, and others.
- On the basis of end user, the global medicinal chemistry for drug discovery market is segmented into contract research organization, academic and research institutes, pharmaceutical and biotechnology companies and others.
Regional Insights: North America dominates the Global Medicinal Chemistry for Drug Discovery Market
The U.S. is anticipated to exhibit the highest growth rate in North America during 2022-2029, primarily attributed to a surge in clinical trials and research focused on chronic disease prevention. As healthcare advancements gain momentum, increased emphasis on identifying preventive measures for chronic ailments propels the U.S. clinical research landscape, fostering substantial market expansion.
China takes the lead in driving growth within the Asia-Pacific market. The target selection segment takes prominence, driven by initiatives fostering research on rare diseases and orphan drugs. China's growing commitment to addressing unmet medical needs in rare diseases encourages substantial investment and collaboration, fueling remarkable progress in target selection for therapeutic interventions.
Within Europe, Germany stands out with the target selection segment taking the forefront. This dominance is attributed to robust collaboration among researchers and pharmaceutical industries. The synergy between research entities and pharmaceutical companies in Germany fosters efficient identification and prioritization of therapeutic targets, bolstering the European market's growth through enhanced partnerships and insights.
To know more about the study visit, https://www.databridgemarketresearch.com/reports/global-medicinal-chemistry-for-drug-discovery-market
Recent Developments in Global Medicinal Chemistry for Drug Discovery Market
- In November 2021, Jubilant Biosys Limited took a significant stride by expanding its facilities to bolster drug discovery chemistry and in-vitro ADME services. This expansion strategically supports its offerings, allowing the company to provide comprehensive solutions, including collaborations with entities such as Turning Point Therapeutics Inc. This move enhances Jubilant Biosys' position in the global medicinal chemistry for drug discovery market, fostering growth and innovation.
- In February 2021, Eurofins made a noteworthy acquisition, bringing Beacon Discovery into its fold. Beacon Discovery's extensive expertise in drug discovery and innovative prowess, particularly in GPCR (G-Protein Coupled Receptor) research, caught Eurofins' attention. Through this strategic move, Eurofins strengthened its foothold in the global medicinal chemistry for drug discovery market, elevating its capabilities and broadening its offerings.
The Prominent Key Players Operating in the Global Medicinal Chemistry for Drug Discovery Market Include:
- Eurofins Scientific (Luxembourg)
- Covance Inc. (now part of the LabCorp Group) (U.S.)
- WuXi Apptec (China)
- Charles River (U.S.)
- Thermo Fisher Scientific, Inc. (U.S.)
- Evotec SE (Germany)
- Piramal Pharma Solutions (India)
- Pfizer, Inc. (U.S.)
- Certara (U.S.)
- Sygnature Discovery Limited (U.K.)
- Malvern Panalytical Ltd (Parent Company Spectris PLC) (U.K.)
- Jubilant Biosys Ltd. (A Jubilant Pharmova Limited Company) (India)
- Taros Chemicals GmbH & Co. KG (Germany)
- Genscript Biotech Corporation (U.S.)
- Nereid Therapeutics Inc. (U.S.)
- BioBlocks, Inc. (U.S.)
- Charnwood Molecular LTD (U.K.)
- Domainex (United Kingdom)
- Aurigene Pharmaceutical Services Ltd. (a subsidiary of Dr. Reddy’s Laboratories Ltd.) (India)
- Selvita (Poland)
- Nanosyn (U.S.)
- Drug Discovery Alliances Inc. (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of global medicinal chemistry for drug discovery market companies contact, https://www.databridgemarketresearch.com/contact
Research Methodology: Global Medicinal Chemistry for Drug Discovery Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
